Clinical trials: End-stage Liver Disease
End Stage Liver Disease, Lung Cancer
Antinociceptive Modalities on Ischemia Reperfusion Injury
Postoperative pain caused by surgery-associated tissue injury is a major concern for all the clinical practitioners. Because it affects multiple systems and induces physiological, immunological and psychological changes.
- Trial name
- NCT01932918
- Testing
- Patient controlled analgesia
- Where
- Taiwan
- Volunteers
- 142 people
- Sponsor
- National Taiwan University Hospital
End Stage Liver Disease
Pilot Trial of Eculizumab Therapy to Reduce Preservation Injury in Human Macrosteatotic Liver Transplantation
The number of liver transplants that can be performed is limited by the availability of organs. Livers that are steatotic (i.e., infiltrated by triglycerides and other fatty substances) are usually not used for transplants, due…
- Trial name
- NCT03468140
- Testing
- Eculizumab, No intervention
- Where
- United States
- Sponsor
- Yale University
Acute Liver Failure, Mitochondrial Diseases
Longitudinal Study of Mitochondrial Hepatopathies
The specific aims of this study are (1) to determine the clinical phenotypes and natural history of hepatic RC and FAO disorders, (2) to determine the correlation between genotype and phenotype, (3) to determine if circulating…
- Conditions
- Acute Liver Failure, Mitochondrial Diseases, End Stage Liver Disease, Respiratory Chain Deficiencies, Mitochondrial
- Trial name
- MITOHEP (NCT01148550)
- Where
- 16 sites in United States, Canada
- Volunteers
- 90 people
- Sponsor
- Arbor Research Collaborative for Health
Hepatitis B, ESRD (End Stage Renal Disease)
Comparing Hepatitis B Vaccination Schedules in Patients on Hemodialysis
People with kidney failure who are on dialysis have a weaker immune response to the hepatitis B vaccine than healthy people. Even after vaccination, many dialysis patients do not develop enough protection against hepatitis B…
- Conditions
- Hepatitis B, ESRD (End Stage Renal Disease), Kidney Failure, Chronic
- Trial name
- 3v4-HEP-DOSE (NCT07784452)
- Testing
- Recombinant Hepatitis B Vaccine - 3-Dose Schedule, Recombinant Hepatitis B Vaccine - 4-Dose Schedule
- Where
- Pakistan
- Volunteers
- 104 people
- Sponsor
- Jinnah Hospital
Hepatitis C, Chronic
HELPS Study - A Study of Peginterferon Alfa-2a (Pegasys) in Patients With Chronic Hepatitis C (CHC) and End-Stage Renal Disease (ESRD)
This study evaluated the safety and efficacy of peginterferon alfa-2a monotherapy in participants with Chronic Hepatitis C (CHC) who have End-Stage Renal Disease (ESRD) and were undergoing hemodialysis.
- Trial name
- NCT02806505
- Testing
- Peginterferon alfa-2a
- Where
- 22 sites in Austria, Brazil and 6 more
- Volunteers
- 81 people
- Sponsor
- Hoffmann-La Roche
Metastatic Cancer, Congestive Heart Failure
Reducing Disparities in the Quality of Advance Care Planning for Older Adults
This study compares the effectiveness of two different approaches to advance care planning among older African Americans and older Whites living in the community.
- Conditions
- Metastatic Cancer, Congestive Heart Failure, Chronic Obstructive Pulmonary Disease, Parkinson Disease
- Trial name
- EQUALACP (NCT03516994)
- Testing
- Respecting Choices First Steps, Five Wishes Form
- Where
- 4 sites in United States
- Volunteers
- 790 people
- Sponsor
- Duke University
Liver Transplantation, Tranexamic Acid
Efficacy and Safety of Tranexamic Acid in Adult Liver Transplantation---ESTA Trial
We propose a multi-center randomized trial to test the primary hypothesis that tranexamic acid is superior to placebo on blood loss in adult orthotopic liver transplantation within the initial 24 hours and that tranexamic acid is…
- Conditions
- Liver Transplantation, Tranexamic Acid, End-stage Liver Disease (ESLD)
- Trial name
- ESTA (NCT07157631)
- Testing
- tranexamic acid, 0.9 % saline
- Where
- China
- Volunteers
- 1,546 people
- Sponsor
- RenJi Hospital
Liver Transplantation (LT), End-Stage Liver Disease
Physical and Cognitive Outcomes After Post-Transplant Physiotherapy in Liver Transplant Recipients
Liver transplantation is the most effective treatment for end-stage liver disease. However, many recipients continue to experience problems such as reduced physical function, impaired balance, fatigue, and cognitive difficulties…
- Trial name
- NCT07694245
- Testing
- Routine Post-Transplant Physiotherapy
- Where
- Turkey (Türkiye)
- Volunteers
- 106 people
- Sponsor
- Hasan Kalyoncu University
Liver Transplantation, End-stage Liver Disease (ESLD)
Restrictive Fluid Management In Liver Transplantation (REFIL) - Pilot
Hypothesis: A Canadian multicentre clinical trial is feasible. Study Design: Multicenter internal pilot parallel arm randomized controlled trial.
- Trial name
- REFIL-1 (NCT05647733)
- Testing
- Low splanchnic blood volume restrictive fluid management strategy, Optimized cardiac output liberal fluid management strategy, Phlebotomy
- Where
- 4 sites in Canada
- Volunteers
- 138 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Liver Transplantation, Immune Tolerance
Immune Tolerance Induction After Liver Transplantation
This clinical trial is being conducted to help liver transplant recipients safely discontinue toxic immunosuppressive drugs years after surgery.
- Conditions
- Liver Transplantation, Immune Tolerance, Immune Tolerance/Drug Effects, Graft Survival
- Trial name
- iTILT (NCT07269041)
- Testing
- Donor Hematopoietic Stem and Progenitor Cell Infusion
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of California, Los Angeles
Critical Illness, Chronic Disease
Improving Communication About Serious Illness
The purpose of this study is to improve care delivered to patients with serious illness by enhancing communication among patients, families, and clinicians in the outpatient setting.
- Conditions
- Critical Illness, Chronic Disease, Terminal Care, Palliative Care
- Trial name
- ICSI (NCT01933789)
- Testing
- Communication Feedback Form for Patients with Serious Illness
- Where
- 6 sites in United States
- Volunteers
- 817 people
- Sponsor
- University of Washington
Hepatitis B, Acute-On-Chronic Liver Failure
RL-1 Novel Human-derived Bio-artificial Liver Treatment in Patients of HBV Related ACLF
This study is to investigate the clinical efficacy and safety of RL-1 Novel Human-derived Bio-artificial Liver treatment in patients with Hepatitis b virus related acute-on-chronic liver failure.
- Trial name
- NCT04195282
- Testing
- Plasma exchange, RL-1 Novel Human-derived Bio-artificial Liver Treatment
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Liver Transplant Disorder
Developing Prediction Models for Allograft Failure After Liver Transplantation
Prompt identification of allograft failure (AF) is highly desirable to address patients to liver retransplantation, in order to maximize results and preserve patients safety.
- Trial name
- IMPROVEMENT (NCT05289609)
- Testing
- Liver Transplantation
- Where
- 18 sites in United States, Argentina and 9 more
- Volunteers
- 5,000 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Liver Cirrhosis, Decompensated Cirrhosis of Liver
Validation of New Prognostic Biomarkers in Patients With Decompensated Cirrhosis
The study aims to test the effectiveness of new biomarkers (measurable molecules in our body) in predicting the health outcome of patients with liver cirrhosis discharged from the hospital after a serious complication of the…
- Trial name
- PROSPECT (NCT06855056)
- Where
- 9 sites in France, Germany and 3 more
- Volunteers
- 189 people
- Sponsor
- European Foundation for Study of Chronic Liver Failure
Acute Kidney Injury, Hyperglycemia
Impact of Glycemic Control After Reperfusion on Acute Kidney Injury in Living Donor Liver Transplantation
This retrospective cohort study of patients classified by the blood glucose level after reperfusion in liver transplantation repicient.
- Conditions
- Acute Kidney Injury, Hyperglycemia, Hypoglycemia, End Stage Liver Disease
- Trial name
- NCT06320730
- Testing
- Observational study, records of blood glucose level after reperfusion
- Where
- South Korea
- Volunteers
- 3,790 people
- Sponsor
- Asan Medical Center
Cirrhosis
Study Of Bacterial/Fungal Infections in Hospitalized Patients With Liver Cirrhosis in China
This is a national, investigator-initiated, multicenter, prospective, observational, web-based registry in hospitalized patients with cirrhosis across China.
- Trial name
- SONIC (NCT03676777)
- Where
- 23 sites in China
- Volunteers
- 1,232 people
- Sponsor
- Ruijin Hospital
End Stage Liver Disease
Spray Diathermy Versus Harmonic Scalpel Technique for Hepatic Parenchymal Transection
Consecutive patients, who were treated for end stage liver cirrhosis by LDLT were included in this a prospective study.Patients enrolled in the study divided into two groups according to the day of surgery.
- Trial name
- LDLT (NCT02617498)
- Testing
- harmonic scalpel, spray mode diathermy
- Volunteers
- 80 people
- Sponsor
- Mansoura University
Gastric Cancer, Complication,Postoperative
The Model for End-Stage Liver Disease Sodium (MELD-Na) Score in Non-cirrhotic Patients With Gastric Cancer
Gastric cancer is the fifth most common cancer worldwide. Gastrectomy with lymphadenectomy is still the most effective treatment modality, depending on the stage and location.
- Conditions
- Gastric Cancer, Complication,Postoperative, Complications; Gastrointestinal, Postoperative, Morality
- Trial name
- NCT04791293
- Testing
- MELD-Na score
- Where
- Turkey (Türkiye)
- Volunteers
- 159 people
- Sponsor
- Istanbul Training and Research Hospital
Liver Failure, Acute on Chronic
MSC-EV in Acute-on-Chronic Liver Failure After Liver Transplantation
Acute-on-chronic liver failure refers to a liver failure syndrome in which some patients with chronic liver disease with relatively stable liver function suffer from acute liver decompensation and liver failure due to the effects…
- Trial name
- NCT05881668
- Testing
- MSC-EV
- Where
- China
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Alcoholic Liver Cirrhosis
Dose Finding Study to Assess Safety and Efficacy of Stem Cells in Liver Cirrhosis
This study will evaluate the safety and efficacy of mesenchymal stem cells in patients with cirrhosis of liver. Stem cells will be injected into the hepatic artery. Improvement in various parameters will be observed over 2 years.
- Trial name
- NCT01591200
- Testing
- Allogeneic Mesenchymal Stem Cells
- Where
- 10 sites in India
- Volunteers
- 40 people
- Sponsor
- Stempeutics Research Pvt Ltd